102 related articles for article (PubMed ID: 26499992)
1. Role of cysteinyl leukotriene receptor-1 antagonists in treatment of experimentally induced mammary tumor: does montelukast modulate antitumor and immunosuppressant effects of doxorubicin?
El-Sisi Ael-D; Sokar SS; Salem TA; Abu Risha SE
Toxicol Ind Health; 2015 Nov; 31(11):1024-36. PubMed ID: 26499992
[TBL] [Abstract][Full Text] [Related]
2. PPARγ-dependent anti-tumor and immunomodulatory actions of pioglitazone.
El-Sisi AE; Sokar SS; Salem TA; Abu Risha SE
J Immunotoxicol; 2015; 12(4):308-16. PubMed ID: 25425470
[TBL] [Abstract][Full Text] [Related]
3. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling.
Lai J; Mei ZL; Wang H; Hu M; Long Y; Miao MX; Li N; Hong H
Neurochem Int; 2014 Sep; 75():26-31. PubMed ID: 24879954
[TBL] [Abstract][Full Text] [Related]
4. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
[TBL] [Abstract][Full Text] [Related]
5. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats.
Abdel-Raheem IT; Khedr NF
Naunyn Schmiedebergs Arch Pharmacol; 2014 Apr; 387(4):341-53. PubMed ID: 24363042
[TBL] [Abstract][Full Text] [Related]
9. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
[TBL] [Abstract][Full Text] [Related]
10. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity.
Tahan F; Jazrawi E; Moodley T; Rovati GE; Adcock IM
Clin Exp Allergy; 2008 May; 38(5):805-11. PubMed ID: 18325031
[TBL] [Abstract][Full Text] [Related]
11. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules.
Maeba S; Ichiyama T; Ueno Y; Makata H; Matsubara T; Furukawa S
Ann Allergy Asthma Immunol; 2005 Jun; 94(6):670-4. PubMed ID: 15984600
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
13. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
Lenz QF; Arroyo DS; Temp FR; Poersch AB; Masson CJ; Jesse AC; Marafiga JR; Reschke CR; Iribarren P; Mello CF
Neuroscience; 2014 Sep; 277():859-71. PubMed ID: 25090924
[TBL] [Abstract][Full Text] [Related]
14. Cysteinyl leukotriene receptor antagonist epigenetically modulates cytokine expression and maturation of human myeloid dendritic cells.
Kuo CH; Yang SN; Kuo HF; Lee MS; Huang MY; Huang SK; Lin YC; Hsieh CC; Hung CH
Pulm Pharmacol Ther; 2016 Aug; 39():28-37. PubMed ID: 27312202
[TBL] [Abstract][Full Text] [Related]
15. Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1.
Biagioli M; Carino A; Marchianò S; Roselli R; Di Giorgio C; Bordoni M; Fiorucci C; Sepe V; Conflitti P; Limongelli V; Distrutti E; Baldoni M; Zampella A; Fiorucci S
Biochem Pharmacol; 2020 Jul; 177():113987. PubMed ID: 32330496
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiological role of mast cells in collagen-induced arthritis: study with a cysteinyl leukotriene receptor antagonist, montelukast.
Shiota N; Shimoura K; Okunishi H
Eur J Pharmacol; 2006 Oct; 548(1-3):158-66. PubMed ID: 16949072
[TBL] [Abstract][Full Text] [Related]
17. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury.
Zhou C; Shi X; Huang H; Zhu Y; Wu Y
Anesth Analg; 2014 May; 118(5):1090-6. PubMed ID: 24686047
[TBL] [Abstract][Full Text] [Related]
18. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
19. Montelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells.
Tsai MJ; Chang WA; Tsai PH; Wu CY; Ho YW; Yen MC; Lin YS; Kuo PL; Hsu YL
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28672809
[TBL] [Abstract][Full Text] [Related]
20. Cysteinyl leukotriene receptor 1 promotes 5-fluorouracil resistance and resistance-derived stemness in colon cancer cells.
Satapathy SR; Sjölander A
Cancer Lett; 2020 Sep; 488():50-62. PubMed ID: 32474153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
